US Liquid Biopsy Market by Product Type, Application, and End-Use: Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently released a comprehensive report on the US Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges. This detailed report outlines the market structure and growth potential over the forecast period.

Key Insights:

US Liquid Biopsy Market Size (2024E): US$4.1 Bn
Projected Market Value (2031F): US$10.5 Bn
US Market Growth Rate (CAGR 2024 to 2031): 14.3%

US Liquid Biopsy Market - Report Scope:

Liquid biopsy is a non-invasive diagnostic tool used to detect cancer and monitor its progression by analyzing biomarkers such as circulating tumor cells (CTCs), cell-free DNA, and exosomes in the blood. The market's growth is driven by rising cancer cases, technological advancements, and increasing demand for minimally invasive diagnostic solutions.

Market Growth Drivers:

The liquid biopsy market is driven by several factors, including the rising incidence of cancer, an increasing preference for non-invasive diagnostic techniques, and advancements in next-generation sequencing (NGS). The technology enables early cancer detection and provides valuable insights into tumor genetics, allowing for personalized treatment strategies. The growing adoption of liquid biopsies for monitoring minimal residual disease (MRD) and treatment response also boosts market growth.

Market Restraints:

Despite its promising potential, the liquid biopsy market faces challenges such as concerns over lower sensitivity in some tests, particularly in detecting circulating tumor DNA (ctDNA). This may result in false negatives, hindering its diagnostic accuracy. Regulatory hurdles and issues related to reimbursement policies further impede the adoption of liquid biopsy technologies.

Market Opportunities:

The US liquid biopsy market presents significant growth opportunities, driven by advancements in biomarker detection and the development of companion diagnostics for personalized cancer therapies. Additionally, the expansion of liquid biopsy applications in non-cancer indications and the introduction of innovative assays for minimal residual disease detection provide new avenues for market growth.

Key Questions Answered in the Report:

What are the primary factors driving the US Liquid Biopsy Market?
Which liquid biopsy biomarkers (CTCs, cell-free DNA, etc.) are seeing the highest clinical use?
How are advancements in NGS impacting the competitive landscape of the liquid biopsy market?
Who are the leading players in the US Liquid Biopsy Market, and what strategies are they using to maintain their market positions?
What are the emerging trends and future prospects for the US Liquid Biopsy Market?

Competitive Intelligence and Business Strategy:

Leading players in the US Liquid Biopsy Market, including companies like Guardant Health, Biocept, Inc., and Qiagen N.V., are focusing on product innovation, partnerships, and regulatory approvals to strengthen their market positions. These companies are investing in expanding their assay portfolios, enhancing sensitivity and specificity, and forming strategic collaborations with academic institutions and clinical laboratories. Additionally, efforts to secure reimbursement policies and regulatory endorsements are critical to driving adoption in the US market.

Key Companies Profiled:

Guardant Health
Biocept, Inc.
Qiagen N.V.
Illumina, Inc.
Thermo Fisher Scientific, Inc.
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
F. Hoffmann-La Roche Ltd
ANGLE plc
BIODESIX

Key Segments of the US Liquid Biopsy Market:

By Product Type:

Assay Kits
Instruments
Services

By Biomarker:

Cell-free DNA (cfDNA)
Circulating Tumor Cells (CTCs)
Cell-Free RNA
Exosomes and Extracellular Vesicles
Others

By Application:

Cancer Application
Non-cancer Application

By End User:

Academic and Research Institutions
Clinical Laboratories
Pharmaceutical and Biotechnology Companies
Others

By Region:

Northeast
Midwest
Southeast
Southwest
West

Product Code: PMRREP34545

1. Executive Summary

1.1. US Liquid Biopsy Market Snapshot, 2024-2033
1.2. Market Opportunity Assessment, 2024-2033, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. US Sectorial Outlook
- 2.3.2. US GDP Growth Outlook
- 2.3.3. US Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Product Adoption Analysis
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
- 3.4.1. List of Distribution Channel/Marketplaces
  - 3.4.1.1. Retail
  - 3.4.1.2. Audiology
  - 3.4.1.3. E-Commerce
- 3.4.2. List of End User (Industry)
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis

4. US Liquid Biopsy Market Outlook: Historical (2019-2023) and Forecast (2024-2033)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2033
4.3. US Liquid Biopsy Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024-2033
  - 4.3.3.1. Assay Kits
  - 4.3.3.2. Services
  - 4.3.3.3. Instruments
4.4. Market Attractiveness Analysis: Product Type
4.5. US Liquid Biopsy Market Outlook: Biomarkers
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Biomarkers, 2019-2023
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarkers, 2024-2033
  - 4.5.3.1. Cell-free DNA Circulating
  - 4.5.3.2. Cell-Free RNA
  - 4.5.3.3. Circulating Tumor Cells (CTCs)
  - 4.5.3.4. Exosomes and Extracellular Vesicles
  - 4.5.3.5. Others
4.6. Market Attractiveness Analysis: Biomarkers
4.7. US Liquid Biopsy Market Outlook: Application
- 4.7.1. Introduction / Key Findings
- 4.7.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
- 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2033
  - 4.7.3.1. Cancer Application
    - 4.7.3.1.1. Lung Cancer
    - 4.7.3.1.2. Breast Cancer
    - 4.7.3.1.3. Colorectal Cancer
    - 4.7.3.1.4. Prostate Cancer
    - 4.7.3.1.5. Others
  - 4.7.3.2. Non-cancer Application
4.8. Market Attractiveness Analysis: Application
4.9. US Liquid Biopsy Market Outlook: End-user
- 4.9.1. Introduction / Key Findings
- 4.9.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2023
- 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2033
  - 4.9.3.1. Academic and Research Institutions
  - 4.9.3.2. Clinical Laboratories
  - 4.9.3.3. Pharmaceutical and Biotechnology Companies
  - 4.9.3.4. Other
4.10. Market Attractiveness Analysis: End-user

5. US Liquid Biopsy Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2033
- 5.3.1. Northeast
- 5.3.2. Midwest
- 5.3.3. Southeast
- 5.3.4. Southwest
- 5.3.5. West
5.4. Market Attractiveness Analysis: Region

6. Northeast Liquid Biopsy Market Outlook: Historical (2019-2023) and Forecast (2024-2033)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 6.3.1. By Country
- 6.3.2. By Product Type
- 6.3.3. By Biomarkers
- 6.3.4. By Application
- 6.3.5. By End-user
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024-2033
- 6.4.1. Assay Kits
- 6.4.2. Services
- 6.4.3. Instruments
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarkers, 2024-2033
- 6.5.1. Cell-free DNA Circulating
- 6.5.2. Cell-Free RNA
- 6.5.3. Circulating Tumor Cells (CTCs)
- 6.5.4. Exosomes and Extracellular Vesicles
- 6.5.5. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2033
- 6.6.1. Cancer Application
  - 6.6.1.1. Lung Cancer
  - 6.6.1.2. Breast Cancer
  - 6.6.1.3. Colorectal Cancer
  - 6.6.1.4. Prostate Cancer
  - 6.6.1.5. Others
- 6.6.2. Non-cancer Application
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2033
- 6.7.1. Academic and Research Institutions
- 6.7.2. Clinical Laboratories
- 6.7.3. Pharmaceutical and Biotechnology Companies
- 6.7.4. Other
6.8. Market Attractiveness Analysis

7. Midwest Liquid Biopsy Market Outlook: Historical (2019-2023) and Forecast (2024-2033)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 7.3.1. By Country
- 7.3.2. By Product Type
- 7.3.3. By Biomarkers
- 7.3.4. By Application
- 7.3.5. By End-user
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024-2033
- 7.4.1. Assay Kits
- 7.4.2. Services
- 7.4.3. Instruments
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarkers, 2024-2033
- 7.5.1. Cell-free DNA Circulating
- 7.5.2. Cell-Free RNA
- 7.5.3. Circulating Tumor Cells (CTCs)
- 7.5.4. Exosomes and Extracellular Vesicles
- 7.5.5. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2033
- 7.6.1. Cancer Application
  - 7.6.1.1. Lung Cancer
  - 7.6.1.2. Breast Cancer
  - 7.6.1.3. Colorectal Cancer
  - 7.6.1.4. Prostate Cancer
  - 7.6.1.5. Others
- 7.6.2. Non-cancer Application
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2033
- 7.7.1. Academic and Research Institutions
- 7.7.2. Clinical Laboratories
- 7.7.3. Pharmaceutical and Biotechnology Companies
- 7.7.4. Other
7.8. Market Attractiveness Analysis

8. Southeast Liquid Biopsy Market Outlook: Historical (2019-2023) and Forecast (2024-2033)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 8.3.1. By Country
- 8.3.2. By Product Type
- 8.3.3. By Biomarkers
- 8.3.4. By Application
- 8.3.5. By End-user
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024-2033
- 8.4.1. Assay Kits
- 8.4.2. Services
- 8.4.3. Instruments
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarkers, 2024-2033
- 8.5.1. Cell-free DNA Circulating
- 8.5.2. Cell-Free RNA
- 8.5.3. Circulating Tumor Cells (CTCs)
- 8.5.4. Exosomes and Extracellular Vesicles
- 8.5.5. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2033
- 8.6.1. Cancer Application
  - 8.6.1.1. Lung Cancer
  - 8.6.1.2. Breast Cancer
  - 8.6.1.3. Colorectal Cancer
  - 8.6.1.4. Prostate Cancer
  - 8.6.1.5. Others
- 8.6.2. Non-cancer Application
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2033
- 8.7.1. Academic and Research Institutions
- 8.7.2. Clinical Laboratories
- 8.7.3. Pharmaceutical and Biotechnology Companies
- 8.7.4. Other
8.8. Market Attractiveness Analysis

9. Southwest Liquid Biopsy Market Outlook: Historical (2019-2023) and Forecast (2024-2033)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 9.3.1. By Country
- 9.3.2. By Product Type
- 9.3.3. By Biomarkers
- 9.3.4. By Application
- 9.3.5. By End-user
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024-2033
- 9.4.1. Assay Kits
- 9.4.2. Services
- 9.4.3. Instruments
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarkers, 2024-2033
- 9.5.1. Cell-free DNA Circulating
- 9.5.2. Cell-Free RNA
- 9.5.3. Circulating Tumor Cells (CTCs)
- 9.5.4. Exosomes and Extracellular Vesicles
- 9.5.5. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2033
- 9.6.1. Cancer Application
  - 9.6.1.1. Lung Cancer
  - 9.6.1.2. Breast Cancer
  - 9.6.1.3. Colorectal Cancer
  - 9.6.1.4. Prostate Cancer
  - 9.6.1.5. Others
- 9.6.2. Non-cancer Application
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2033
- 9.7.1. Academic and Research Institutions
- 9.7.2. Clinical Laboratories
- 9.7.3. Pharmaceutical and Biotechnology Companies
- 9.7.4. Other
9.8. Market Attractiveness Analysis

10. West Liquid Biopsy Market Outlook: Historical (2019-2023) and Forecast (2024-2033)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 10.3.1. By Country
- 10.3.2. By Product Type
- 10.3.3. By Biomarkers
- 10.3.4. By Application
- 10.3.5. By End-user
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024-2033
- 10.4.1. Assay Kits
- 10.4.2. Services
- 10.4.3. Instruments
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarkers, 2024-2033
- 10.5.1. Cell-free DNA Circulating
- 10.5.2. Cell-Free RNA
- 10.5.3. Circulating Tumor Cells (CTCs)
- 10.5.4. Exosomes and Extracellular Vesicles
- 10.5.5. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2033
- 10.6.1. Cancer Application
  - 10.6.1.1. Lung Cancer
  - 10.6.1.2. Breast Cancer
  - 10.6.1.3. Colorectal Cancer
  - 10.6.1.4. Prostate Cancer
  - 10.6.1.5. Others
- 10.6.2. Non-cancer Application
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2033
- 10.7.1. Academic and Research Institutions
- 10.7.2. Clinical Laboratories
- 10.7.3. Pharmaceutical and Biotechnology Companies
- 10.7.4. Other
10.8. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2024
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Dashboard
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Biocept, Inc.
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Products
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Qiagen N.V.
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Products
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. Illumina, Inc.
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Products
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Myriad Genetics, Inc.
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Products
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Thermo Fisher Scientific, Inc.
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Products
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. Guardant Health
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Products
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. F. Hoffmann-La Roche Ltd
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Products
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. ANGLE plc.
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Products
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. BIODESIX
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Products
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. NeoGenomics Laboratories, Inc.
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Products
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations